和誉-B：口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration (NMPA) in China for the clinical trial application (IND) of its oral, highly active, and selective small molecule KRAS G12D inhibitor, ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The clinical trial application for ABSK141 has been approved by NMPA [1] - ABSK141 is designed for patients with advanced solid tumors that have the KRAS G12D mutation [1] - The drug is characterized as an oral, highly active, and highly selective small molecule inhibitor [1]